Back to Network
Icahn School of Medicine at Mount Sinai
ORGANIZATIONthe Further Cardiovascular Outcomes Research
ORGANIZATION3
Shared Docs
3
Same-Page
3 / 3
Mentions
Document Mentions (3 shared documents)
2 mentions1 same-page
Page ?Same page
ate: Fri, 24 Mar 2017 11:17:36 +0000 Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730
ply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2017 American College of Cardiology Scientific Session in Was
2 mentions1 same-page
Page ?Same page
t 7:17:36 AM EDT To: Lesley Groff < Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730
y Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was
2 mentions1 same-page
Page ?Same page
hanks! On Mar 24, 2017, at 7:17 AM, Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730
Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was
Sponsored
Mutual Connections (15)
Entities connected to both Icahn School of Medicine at Mount Sinai and the Further Cardiovascular Outcomes Research
Jeffrey Epstein
PERSON45 w/ Icahn·3 w/ the
Mount Sinai
ORGANIZATION33 w/ Icahn·3 w/ the
Lesley Groff
PERSON32 w/ Icahn·3 w/ the
RS
Rony Shimony
PERSON22 w/ Icahn·3 w/ the
SA
Sabatine
PERSON3 w/ Icahn·3 w/ the
GR
Giugliano RP
PERSON3 w/ Icahn·3 w/ the
Evolocumab
ORGANIZATION3 w/ Icahn·3 w/ the
American College of Cardiology 2017 Scientific Session
ORGANIZATION3 w/ Icahn·3 w/ the
Keech AC
ORGANIZATION3 w/ Icahn·3 w/ the
American Medical Communications
ORGANIZATION3 w/ Icahn·3 w/ the
Harvard Medical School
ORGANIZATION3 w/ Icahn·3 w/ the
Manalapan
LOCATION3 w/ Icahn·3 w/ the
MS
Marc S. Sabatine
PERSON3 w/ Icahn·3 w/ the
Sabatine M. Primary
ORGANIZATION2 w/ Icahn·2 w/ the
Brigham and Women's Hospital
ORGANIZATION2 w/ Icahn·2 w/ the